Antibiotic-Resistant Gonorrhea: Global Rise and Concerns
- This self-check summarizes key data from the provided text regarding gonorrhea and the growing threat of antibiotic resistance.
- * Gonorrhea is a common bacterial sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae.
- * Neisseria gonorrhoeae is evolving to resist antibiotics.
Gonorrhea & Antibiotic Resistance: A Self-Check
This self-check summarizes key data from the provided text regarding gonorrhea and the growing threat of antibiotic resistance.
1. What is Gonorrhea?
* Gonorrhea is a common bacterial sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae.
* Globally,approximately 82 million cases are estimated annually.
* In the United states, the CDC estimates around 1.6 million cases each year.
* Many infections are asymptomatic (show no symptoms).
* Symptoms, when present, can include:
* Discharge from the penis or vagina
* Burning sensation during urination
* Swollen testicles (in men)
* Untreated gonorrhea can lead too infertility in both men and women, and other health issues.
2. The Problem of Antibiotic Resistance
* Neisseria gonorrhoeae is evolving to resist antibiotics.
* The bacteria has already developed resistance to:
* sulfanilamides
* penicillins
* Tetracyclines
* Fluoroquinolones
* Currently, cephalosporins (specifically ceftriaxone) are the primary effective treatment. Azithromycin is often used in combination.
* Increasing cases are emerging were standard treatment (ceftriaxone alone or with azithromycin) is not sufficient,requiring multiple antibiotics.
3. WHO Data on Resistance (2022-2024)
The following table summarizes the rise in antibiotic resistance based on data from the WHO’s Enhanced Gonococcal Antimicrobial Surveillance Program (ESGAP):
| Antibiotic | Resistance rate (2022) | Resistance Rate (2024) |
|---|---|---|
| Ceftriaxone | 0.8% | 5% |
| Cefixime | 1.7% | 11% |
| Azithromycin | 0.5% | 4% |
| Ciprofloxacin | < 1% | 95% |
4.Potential New Treatments
* Zoliflodacin and gefitibacic are two new antibiotics showing promise in treating resistant gonorrhea.
* These are currently under development and offer hope for future treatment options.
5.Key Links
* WHO Report: https://www.who.int/publications/i/item/9789240117297
* ASHA (American Sexual Health Association) – Gonorrhea: https://www.ashasexualhealth.org/gonorrhea/
* ASHA – New Antibiotic for Resistant Gonorrhea: https://www.ashasexualhealth.org/new-antibiotic-shows-promise-in-treating-resistant-gonorrhea/
* ASHA – stds A to Z: https://www.ashasexualhealth.org/stds_a_to_z/